NCT01371175View on ClinicalTrials.gov

A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

May 31, 2005

Conditions
HIV Infections
Interventions
BIOLOGICAL

DNA.HIVA

0.5mg DNA.HIVA or placebo

BIOLOGICAL

MVA.HIVA

5x10\^6 pfu MVA or placebo

BIOLOGICAL

MVA.HIVA

5x10\^7 pfu MVA or placebo

BIOLOGICAL

MVA.HIVA

2.5x10\^8 pfu MVA or placebo

Trial Locations (2)

Unknown

KAVI (Kenya AIDS Vaccine Initiative), Nairobi

Guys and St. Thomas' Hospital, London

All Listed Sponsors
collaborator

Medical Research Council-Oxford

UNKNOWN

collaborator

University of Nairobi

OTHER

lead

International AIDS Vaccine Initiative

NETWORK

NCT01371175 - A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers | Biotech Hunter | Biotech Hunter